

Romain Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2204188/publications.pdf>

Version: 2024-02-01

87
papers

2,460
citations

257101

24
h-index

315357

38
g-index

103
all docs

103
docs citations

103
times ranked

3995
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
2	Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. <i>Digestive and Liver Disease</i> , 2023, 55, 276-282.	0.4	1
3	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	3.0	5
4	Immune checkpoint inhibitors in colorectal cancer: dream and reality. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 4-6.	3.7	2
5	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification. <i>Cancer Treatment Reviews</i> , 2022, 103, 102325.	3.4	26
6	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
7	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 244-244.	0.8	39
8	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	0.8	12
9	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
10	Immune microenvironment in patients with mismatchâ€repairâ€proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. <i>Molecular Oncology</i> , 2022, 16, 2260-2273.	2.1	5
11	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
12	Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. <i>World Journal of Surgical Oncology</i> , 2022, 20, 131.	0.8	10
13	Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 233-241.	1.8	18
14	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. <i>European Journal of Cancer</i> , 2022, 168, 99-107.	1.3	3
15	Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	0
16	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3606-3606.	0.8	0
17	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3578-3578.	0.8	0
18	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 208-211.	3.0	56
20	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	3.0	5
21	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. <i>Clinical Trials</i> , 2021, 18, 51-60.	0.7	3
22	Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 9-16.	1.3	40
23	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	1.3	32
24	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	1.0	4
25	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
26	Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer. , 2021, 9, e001903.		15
27	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84
28	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
29	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. <i>Cancers</i> , 2021, 13, 1149.	1.7	30
30	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	0.7	4
31	Prevalence of <i>NTRK1/3</i> fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15537-e15537.	0.8	2
32	Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3580-3580.	0.8	1
33	Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 7551-7561.	1.0	3
34	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
35	Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100120.	2.0	42
36	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021, 161, 814-826.e7.	0.6	36

#	ARTICLE	IF	CITATIONS
37	Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)†. <i>Annals of Oncology</i> , 2021, 32, 1267-1275.	0.6	39
38	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	0.8	0
39	Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , 2020, 110, 404-412.	1.2	12
40	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	1.7	65
41	46P [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC). <i>Annals of Oncology</i> , 2020, 31, S1434.	0.6	1
42	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. <i>Cancers</i> , 2020, 12, 1990.	1.7	12
43	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2350.	1.7	30
44	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
45	A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 88, 102059.	3.4	12
46	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , 2020, 38, 1702-1710.	0.8	40
47	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	2.3	56
48	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
49	Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (mCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3006-3006.	0.8	28
50	RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 101-101.	0.8	1
51	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-188.	0.8	2
52	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , 2019, 8, 5079-5088.	1.3	11
53	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
54	Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma. <i>Case Reports in Gastrointestinal Medicine</i> , 2019, 2019, 1-3.	0.2	0

#	ARTICLE	IF	CITATIONS
55	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. <i>Bulletin Du Cancer</i> , 2019, 106, 119-128.	0.6	61
56	Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 824-833.	0.4	25
57	Is it permissible to undertake surgery for adrenal metastases of esophageal adenocarcinomas?. <i>Journal of Visceral Surgery</i> , 2019, 156, 275.	0.4	2
58	Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis—In Reply. <i>JAMA Oncology</i> , 2019, 5, 741.	3.4	3
59	Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1227-1238.	1.1	16
60	Characteristics of <i>BRAF</i> <i>V600E</i> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	1.9	20
61	RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	1.2	9
62	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. <i>JAMA Oncology</i> , 2019, 5, 551.	3.4	178
63	Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. <i>Clinical Rheumatology</i> , 2019, 38, 601-602.	1.0	17
64	Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFC0-0307 trial. <i>Gastric Cancer</i> , 2019, 22, 577-586.	2.7	6
65	Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. <i>Bulletin Du Cancer</i> , 2019, 106, 137-142.	0.6	22
66	Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). <i>European Journal of Cancer</i> , 2019, 107, 46-52.	1.3	14
67	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2109-2115.	3.2	65
68	Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3121-3121.	0.8	1
69	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15046-e15046.	0.8	0
70	Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3519-3519.	0.8	0
71	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. <i>Journal of the National Cancer Institute</i> , 2018, 110, 68-77.	3.0	89
72	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E23-E27.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy. <i>Annals of Oncology</i> , 2018, 29, viii179-viii180.	0.6	6
74	Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4035-4035.	0.8	0
75	Immunotherapy and patients treated for cancer with microsatellite instability. <i>Bulletin Du Cancer</i> , 2017, 104, 42-51.	0.6	64
76	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 9.	1.3	51
77	Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers": <i>Current Treatment Options in Oncology</i> , 2017, 18, 63.	1.3	0
78	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. <i>European Journal of Cancer</i> , 2017, 86, 266-274.	1.3	65
79	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <i>Colorectal Cancer</i> , 2017, 6, 23-31.	0.8	1
80	A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. <i>Annals of Oncology</i> , 2017, 28, v180.	0.6	8
81	Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3563-3563.	0.8	0
82	New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2016, 18, 18.	1.8	12
83	Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14096-e14096.	0.8	0
84	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. <i>Bulletin Du Cancer</i> , 2015, 102, 324-331.	0.6	47
85	Targeting the TGF β 2 pathway for cancer therapy. , 2015, 147, 22-31.		513
86	Targeting cancer cell metabolism in pancreatic adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 16832-16847.	0.8	100
87	Food insecurity in French patients with diabetes. <i>Diabetes and Metabolism</i> , 2014, 40, 314-316.	1.4	3